104
Participants
Start Date
October 15, 2025
Primary Completion Date
February 28, 2029
Study Completion Date
July 31, 2029
IMM2510
IMM2510 administered intravenously once every 2 weeks (Q2W). Dose escalation cohorts will receive ascending doses of IMM2510 (e.g., 10 mg/kg, 20 mg/kg, up to maximum tolerated dose or recommended phase 2 dose).
IMM01
IMM01 administered intravenously once every 2 weeks (Q2W). Dose escalation cohorts will receive ascending doses of IMM01 (e.g., 1 mg/kg, 2 mg/kg, 3mg/kg, up to maximum tolerated dose or recommended phase 2 dose).
Shanghai Gobroad Cancer Hospital China Pharmaceutical University, Shanghai
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
OTHER